Table 3.
Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast.
| IGFBP-2 (µIU/mL) | Co/Ca | Model 1 ORa | Model 2 ORb | Co/Ca | Model 3 ORc |
|---|---|---|---|---|---|
| Q1 (<149.9) | 69/77 | 1.0Ref. | 1.0Ref. | 63/71 | 1.0Ref. |
| Q2 (150.0–225.4) | 69/69 | 0.86 (0.53–1.39) | 1.11 (0.65–1.87) | 61/64 | 1.14 (0.65–1.98) |
| Q3 (225.5–349.5) | 69/78 | 0.88 (0.55–1.40) | 1.09 (0.65–1.84) | 66/74 | 1.03 (0.60–1.78) |
| Q4 (≥349.6) | 68/51 | 0.51 (0.29–0.90) | 0.70 (0.36–1.38) | 68/50 | 0.65 (0.32–1.31) |
| Trend | 0.03 | 0.27 | 0.16 |
aModel 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m2).
bModel 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
cModel 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.